AGA Clinical Practice Update on Interaction Between Oral Direct‐Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review
Amit G. Singal, Joseph K. Lim, Fasiha Kanwal – 30 June 2020
Amit G. Singal, Joseph K. Lim, Fasiha Kanwal – 30 June 2020
Praveena Narayanan, Pramod K. Mistry – 30 June 2020
Madeline Bertha, Haripriya Maddur – 30 June 2020
George V. Papatheodoridis, Thodoris Voulgaris, Margarita Papatheodoridi, W. Ray Kim – 30 June 2020
Adam L. Booth, Shehzad N. Merwat, Sheharyar K. Merwat, Heather L. Stevenson – 30 June 2020
Avash Kalra, J. P. Norvell – 30 June 2020
George V. Papatheodoridis, Thodoris Voulgaris, Margarita Papatheodoridi, W. Ray Kim – 30 June 2020
Yoona Rhee, Edie L. Chan, Sheila L. Eswaran, Costica Aloman, Martin Hertl, Carlos A.Q. Santos – 30 June 2020
Toshihiro Kitajima, Shunji Nagai, Dilip Moonka, Antu Segal, Marwan S. Abouljoud – 30 June 2020
Khurram Bari, Shimul A. Shah, Tiffany E. Kaiser, Robert M. Cohen, Nadeem Anwar, David Kleesattel, Kenneth E. Sherman – 30 June 2020 – Despite adverse effects like hyperglycemia, new‐onset diabetes after transplant (NODAT), and infectious complications, corticosteroid use remains an important part of liver transplantation (LT) immune suppression. Budesonide, a synthetic corticosteroid, undergoes extensive first‐pass hepatic metabolism with only 10% systemic bioavailability, providing an opportunity for an improved toxicity‐therapeutic ratio.